VRTX · VERTEX PHARMACEUTICALS INC / MA

421 filings

VRTX SEC Filings

VERTEX PHARMACEUTICALS INC / MA - 421 total filings

Filing record · 2016–202610-K1110-Q328-K100

Showing 1–50 of 421 filings

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Executive Changes (Oct 20, 2026)

Vertex Pharmaceuticals Incorporated (VRTX) announced a significant addition to its Board of Directors on October 20, 2026, with the appointment of Daniel Brennan. This appointment increases the size of the Board from ten to eleven members. Mr. Brennan brings a wealth of financial expertise, having served as Executive Vice President and Chief Financial Officer of Boston Scientific Corporation until his retirement in June 2025, and holding various senior finance roles there for many years prior. His extensive background in financial leadership is expected to be a valuable asset to Vertex's strategic and financial oversight. In addition to his extensive corporate finance experience, Mr. Brennan has a strong track record of public company board service, currently sitting on the boards of Waters Corporation and Madrigal Pharmaceuticals, and previously serving on Nuance Corporation's board. His appointment to the Audit and Finance Committee will further strengthen the board's financial governance. The company also disclosed that Mr. Brennan received a $400,000 restricted stock unit award upon joining, which is set to vest in October 2027, aligning his interests with long-term shareholder value.

Oct 20, 2026 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Executive Changes (Sep 1, 2026)

Vertex Pharmaceuticals Incorporated announced a significant leadership transition in its finance department with the appointment of Jonathan Poole as Executive Vice President and Chief Financial Officer (CFO), effective January 1, 2027. Mr. Poole, a seasoned finance executive with prior CFO experience at Evelo Biosciences and Genocea Biosciences, and extensive background at Shire plc, will succeed Charles F. Wagner, Jr. Mr. Wagner will transition from his CFO responsibilities to focus solely on his role as Executive Vice President and Chief Operating Officer. This appointment brings a well-qualified executive into a critical financial leadership position within Vertex. Investors should note the details of Mr. Poole's compensation package, which includes a $750,000 base salary and a 90% target annual bonus. The agreements also outline severance provisions for termination without cause or resignation for good reason, including salary continuation and accelerated equity vesting, as well as change of control provisions designed to retain key talent during potential acquisition scenarios.

Sep 1, 2026 10-Q

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q2 Ended Jun 30, 2026

Vertex Pharmaceuticals reported robust financial performance for the six months ended June 30, 2026, demonstrating significant revenue growth and continued profitability. Total revenues reached $6.32 billion, a 10% increase year-over-year, driven by strong sales of its cystic fibrosis (CF) therapies and diversification into new disease areas, notably a substantial jump in ALYFTREK and CASGEVY revenues. Net income for the period was $2.13 billion, up from $1.68 billion in the prior year, reflecting improved operational efficiency and product mix. The company also made significant strategic moves, including the announcement of a $10.0 billion acquisition of Crinetics Pharmaceuticals, Inc., expected to close in the third quarter of 2026, aimed at expanding its therapeutic reach into endocrine diseases. Vertex also secured new financing facilities totaling $5.0 billion to support this acquisition and general corporate purposes. The company maintains a strong liquidity position with $13.6 billion in cash, cash equivalents, and marketable securities as of June 30, 2026, underpinning its operational capabilities and strategic growth initiatives.

Aug 4, 2026 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Aug 3, 2026)

Vertex Pharmaceuticals reported strong second quarter 2026 results, with total revenue up 12% year over year to $3.33 billion. Growth was led by cystic fibrosis (CF) franchise performance, particularly ALYFTREK, which generated $574 million in Q2 versus $157 million a year earlier, while TRIKAFTA/KAFTRIO declined to $2.50 billion from $2.55 billion. GAAP net income was $1.10 billion ($4.31 diluted EPS) and non-GAAP net income was $1.21 billion ($4.73 non-GAAP diluted EPS). Operating expenses rose on JOURNAVX launch investment and renal franchise build-out, and the GAAP effective tax rate increased to 21.0% from 19.5%. Cash and marketable securities reached $13.6 billion, up from $12.3 billion at year-end 2025, aided by operating cash flow and partly offset by share repurchases. management raised full-year 2026 total revenue guidance to $13.1–$13.2 billion from $12.95–$13.1 billion, while reiterating its expense and tax guidance. The guidance excludes the pending acquisition of Crinetics Pharmaceuticals, announced in July at $85.00 per share in cash for an equity value of roughly $10.0 billion (about $8.8 billion net of acquired cash), with closing expected in Q3 2026. That deal would add rare endocrine diseases as a fifth pillar, and management plans updated 2026 guidance after closing. Key near-term catalysts include the povetacicept IgAN PDUFA date of November 30, 2026, the AMPLIFIED Phase 2 inaxaplin data this fall, VX-828 and VX-670 data in the second half of 2026, and the Crinetics closing. Investors should note that the filing itself is a press release furnished under Item 2.02 and is not deemed filed for Section 18 purposes.

Aug 3, 2026 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Material Agreement (Jul 7, 2026)

On July 6, 2026, Vertex Pharmaceuticals (VRTX) signed a definitive merger agreement to acquire Crinetics Pharmaceuticals (CRNX) for $85.00 per share in cash. The deal values Crinetics at about $10.0 billion in equity, or $8.8 billion net of cash. Both boards unanimously approved it. Crinetics will become a wholly owned Vertex subsidiary through a reverse triangular merger. Closing requires Crinetics stockholder approval, HSR clearance and any required foreign clearances, and is expected in Q3 2026. The deal is not subject to a financing condition. Strategically, Vertex is adding two late-stage endocrinology assets. PALSONIFY is an oral, once-daily treatment for acromegaly, approved by the FDA and EMA and launched in the U.S. in October 2025. Atumelnant, an oral ACTH receptor antagonist, is in pivotal development for congenital adrenal hyperplasia (CAH) and has Phase 2 data in ACTH-dependent Cushing's syndrome. Vertex says the two assets have roughly $5 billion or more in combined peak annual revenue potential. Management expects the deal to accelerate revenue growth, become accretive to non-GAAP operating income in 2029, and modestly affect 2026 revenue and non-GAAP operating expenses, with 2026 guidance to be updated at closing. The deal is funded with cash on hand and a $4.5 billion unsecured 364-day bridge facility from Bank of America, BofA Securities and Morgan Stanley Senior Funding, which is expected to be replaced by permanent financing. Investors should weigh the approximately $350.5 million termination fee payable by Crinetics in specified circumstances, the January 6, 2027 outside date, and the usual risks of pipeline and launch execution.

Jul 7, 2026 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Executive Changes (May 13, 2026)

Vertex Pharmaceuticals Incorporated (VRTX) filed an 8-K on May 13, 2026, detailing the outcomes of its Annual Shareholder Meeting held on the same date. The most significant outcomes include the overwhelming approval of the 2026 Stock and Option Plan, replacing the previous 2013 plan, and the election of all ten nominated directors to the Board. These approvals indicate strong shareholder confidence in the company's leadership and its long-term incentive strategies. Additionally, shareholders ratified the appointment of Ernst & Young LLP as the independent auditor and approved, on an advisory basis, the 2025 executive compensation program. While a shareholder proposal regarding the right to act by written consent received majority approval, the company's proposed 2026 Stock and Option Plan secured substantially higher levels of support, signaling a clear priority for management's compensation and equity-based incentive frameworks from the investor base.

May 13, 2026 10-Q

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q1 Ended Mar 31, 2026

Vertex Pharmaceuticals Inc. reported strong financial performance for the first quarter of 2026, with total revenues increasing by 8% to $2,986.9 million compared to the same period in 2025. This growth was primarily driven by the continued strength of its cystic fibrosis (CF) therapies, particularly ALYFTREK and TRIKAFTA/KAFTRIO, and initial contributions from newer products like CASGEVY and JOURNAVX. Net income saw a significant surge of approximately 59.5% to $1,031.4 million, driven by robust revenue growth and a reduction in total costs and expenses, notably due to the absence of a large intangible asset impairment charge recorded in the prior year. The company also maintained a healthy cash position, with cash, cash equivalents, and marketable securities totaling $12,996.6 million, indicating strong liquidity and financial stability to support ongoing research, development, and commercialization efforts.

May 5, 2026 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (May 4, 2026)

Vertex Pharmaceuticals reported first quarter 2026 results on May 4, 2026, with total revenue of $2.99 billion, up 8% year over year, driven by cystic fibrosis (CF) franchise performance and early contributions from CASGEVY and JOURNAVX. GAAP net income rose to $1.03 billion from $646 million, though the prior-year period carried a $379 million intangible impairment. Non-GAAP diluted EPS was $4.47 versus $4.06 a year earlier. CF product revenue was $2.92 billion, with ALYFTREK ($424 million, up from $54 million) increasingly offsetting a 7% decline in TRIKAFTA/KAFTRIO to $2.35 billion as the mix shifts to the newer product. Management reiterated full-year 2026 guidance of $12.95–13.1 billion in total revenue and at least $500 million in non-CF product revenue. Expenses rose modestly, with non-GAAP R&D, acquired IPR&D and SG&A at $1.29 billion versus $1.23 billion, reflecting JOURNAVX launch spending and build-out of the renal franchise led by povetacicept in IgA nephropathy. Cash and marketable securities reached $13.0 billion, up from $12.3 billion at year-end 2025, supported by operating cash flow and partly offset by share repurchases. The company completed the rolling BLA submission for povetacicept in IgAN under a Priority Review Voucher, which implies a six-month FDA review from acceptance, and it discontinued the VX-522 cystic fibrosis gene-editing program after persistent tolerability issues. For investors, the key questions are the durability of TRIKAFTA's decline against ALYFTREK's ramp, the pace of non-CF revenue growth needed to hit guidance, and regulatory timing for povetacicept and the CASGEVY pediatric submission. The filing is an Item 2.02 earnings release furnished under Exhibit 99.1, so its content is not subject to Section 18 liability.

May 4, 2026 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Executive Changes (Apr 29, 2026)

Vertex Pharmaceuticals Incorporated (VRTX) has filed an 8-K reporting a change in its Board of Directors. Suketu Upadhyay, a current director, has informed the Board of his decision not to stand for re-election at the upcoming 2026 annual meeting of shareholders. This decision stems from Mr. Upadhyay's recent appointment as the forthcoming Chief Financial Officer of Incyte Corporation, a role that presents scheduling conflicts with his board responsibilities at Vertex.

Apr 29, 2026 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Corporate Update (Mar 31, 2026)

Vertex Pharmaceuticals Incorporated (VRTX) has announced a significant regulatory milestone with the completion of its rolling Biologics Licensing Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for povetacicept. This investigational therapy is being pursued for the treatment of immunoglobulin A nephropathy (IgAN) in adults, a condition with significant unmet medical need. The company has leveraged a priority review voucher, which is expected to expedite the FDA's review process. Vertex anticipates an accelerated six-month review timeline from the BLA acceptance date, compared to the standard ten months, potentially bringing this therapy to market sooner if approved.

Mar 31, 2026 10-K

VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2025

Vertex Pharmaceuticals' FY2025 10-K shows a company at an inflection point: total revenues rose 9% to $12.0 billion, operating income swung to $4.2 billion from a $232.9 million loss in 2024 (which had been depressed by a $4.4 billion non-deductible Alpine acquisition charge), and net income reached $3.95 billion, or $15.32 diluted EPS. The core CF franchise remains the economic engine, with TRIKAFTA/KAFTRIO generating $10.3 billion, roughly 86% of product revenue, while newer launches are gaining traction: ALYFTREK contributed $837.8 million, CASGEVY $115.8 million and JOURNAVX $59.6 million. Operating cash flow recovered to $3.6 billion, and cash plus marketable securities grew to $12.3 billion, supporting a $4.0 billion buyback authorization with $3.4 billion still available. The investment case increasingly depends on the pipeline rather than CF. Management expects to complete the povetacicept BLA for IgA nephropathy in the first half of 2026 using a priority review voucher, with interim data pending, and plans to report AMKD interim data in late 2026 or early 2027. Management also expects SG&A and cost of sales to rise in 2026 as JOURNAVX, povetacicept and CASGEVY scale. Key risks include ongoing pricing pressure (the IRA, state PDABs and the proposed GUARD model), the Royalty Pharma arbitration over the ALYFTREK royalty rate (Vertex accounts for 4%, RP asserts roughly 8%), the $379 million impairment of the VX-264 T1D asset, the temporary pause in zimislecel dosing pending a manufacturing analysis, and the August 2025 setback for suzetrigine in broad peripheral neuropathic pain. At the balance-sheet level the company is conservative: it has no drawn debt on its $500 million revolver, an effective tax rate of 14.9%, and a clean audit opinion from Ernst & Young with an unqualified internal-control opinion. Concentration remains high, since substantially all product revenue comes from CF medicines and McKesson accounts for 22% of gross product revenue.

Feb 13, 2026 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Feb 12, 2026)

Vertex Pharmaceuticals reported strong fourth quarter and full year 2025 results, with full year total revenue of $12.0 billion, up 9% year over year, and fourth quarter revenue of $3.19 billion, up 10%. Growth was driven by cystic fibrosis (CF) franchise performance, including the newer ALYFTREK, along with early contributions from CASGEVY and JOURNAVX. GAAP net income for 2025 was $3.95 billion (GAAP diluted EPS $15.32) versus a GAAP net loss of $536 million in 2024, a swing largely attributable to $4.4 billion of acquired IPR&D from the 2024 Alpine Immune Sciences acquisition. Non-GAAP net income was $4.75 billion. Cash, cash equivalents and marketable securities ended the year at $12.3 billion. For 2026, Vertex guided to total revenue of $12.95 billion to $13.1 billion, including $500 million or more from non-CF products. Combined non-GAAP R&D, AIPR&D and SG&A expenses are expected at $5.65 billion to $5.75 billion, and the non-GAAP effective tax rate at 19.5% to 20.5%. Management highlighted several near-term catalysts, including the planned completion of the povetacicept BLA for IgA nephropathy in the first half of 2026 (with a priority review voucher potentially shortening review to six months) and multiple pediatric regulatory submissions. The quarter also included items that flatter the reported results and merit attention. The fourth quarter GAAP tax rate of 10.5% reflected a one-time benefit from previously deferred tax credits, and the full year 2025 results included a $379 million intangible asset impairment charge. Investors should weigh the strong top-line momentum against the pipeline's dependence on pending data readouts and regulatory decisions, as well as the dependence of the business on CF products, which still make up the large majority of revenue.

Feb 12, 2026 10-Q

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q3 Ended Sep 30, 2025

Vertex Pharmaceuticals Inc. reported strong financial results for the third quarter and the first nine months of 2025, demonstrating significant year-over-year growth in product revenues. Total revenues reached $3.1 billion for the quarter, an 11% increase, and $8.8 billion for the nine-month period, up 9%, driven primarily by the sustained demand for their cystic fibrosis (CF) treatments, particularly TRIKAFTA/KAFTRIO, and early contributions from new product launches. The company also highlighted progress in expanding its therapeutic areas beyond CF, with notable advancements in its pipeline for sickle cell disease (SCD), beta-thalassemia (TDT), acute pain, and various kidney and autoimmune diseases. The acquisition of Alpine Immune Sciences in May 2024 continues to be a significant factor, contributing to R&D expenses but also bringing promising candidates like povetacicept into the pipeline. Despite increased operating costs, including R&D and SG&A expenses, driven by commercial investments and pipeline expansion, Vertex maintained robust profitability. The company ended the period with a healthy cash position of $12.0 billion, reflecting strong operating cash flow.

Nov 4, 2025 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Nov 3, 2025)

Vertex Pharmaceuticals reported third quarter 2025 results on November 3, 2025, with total revenue of $3.08 billion, up 11% year over year. U.S. revenue grew 15% to $1.98 billion, driven by continued cystic fibrosis (CF) demand including the newly launched ALYFTREK, early contributions from CASGEVY and JOURNAVX, and favorable CF net pricing. Outside the U.S., revenue rose 4% to $1.10 billion. GAAP net income was $1.08 billion ($4.20 diluted EPS) versus $1.05 billion a year earlier, and non-GAAP net income was $1.24 billion ($4.80 non-GAAP diluted EPS), up from $4.38. Cash and marketable securities totaled $12.0 billion at quarter end. Management refined full-year 2025 guidance. Total revenue is now expected at $11.9 to $12.0 billion, a narrowing at the low end from the prior $11.85 to $12.0 billion range. Combined GAAP R&D, acquired IPR&D and SG&A expenses were raised to $5.65 to $5.8 billion, and non-GAAP expenses to $5.0 to $5.1 billion, reflecting accelerated povetacicept programs and increased JOURNAVX sales and marketing investment. The non-GAAP tax rate guidance was cut sharply to 17% to 18% from 20.5% to 21.5%, due to one-time tax benefits, including Alpine-related R&D credits recognized in Q3 and previously deferred benefits expected in Q4. Investors should treat the tax benefit as non-recurring when judging underlying earnings quality. The filing also highlights pipeline progress, most notably full enrollment of the Phase 3 IgAN study of povetacicept, with the first module of the BLA on track for submission by year-end 2025 and the full submission planned for the first half of 2026. The filing also notes a $379 million intangible asset impairment charge recorded in the first nine months of 2025, and a temporary postponement of zimislecel dosing completion pending a manufacturing analysis. Both are relevant risk items for investors to monitor.

Nov 3, 2025 10-Q

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q2 Ended Jun 30, 2025

Vertex Pharmaceuticals Inc. reported solid financial results for the second quarter and first half of 2025. Total revenues grew 12% year-over-year to $2.96 billion for the quarter, driven by strong performance in product revenues, which increased by 11% to $2.94 billion. This growth was primarily attributed to continued demand for TRIKAFTA/KAFTRIO and the early contributions from new product launches, including ALYFTREK and JOURNAVX. The company also saw significant growth in its pipeline, with key developments in its Type 1 Diabetes, IgA Nephropathy, and Sickle Cell Disease programs. The company reported a net income of $1.03 billion for the quarter, a substantial turnaround from the net loss of $3.59 billion in the prior year period, which was heavily impacted by the Alpine acquisition's R&D expenses. For the six-month period, net income was $1.68 billion, compared to a net loss of $2.49 billion in the prior year. The company's cash position remains strong, with total cash, cash equivalents, and marketable securities reaching $12.0 billion. Management expects existing liquidity to be sufficient for at least the next twelve months, supported by ongoing operations and a robust product portfolio.

Aug 5, 2025 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Aug 4, 2025)

Vertex Pharmaceuticals (VRTX) reported second quarter 2025 results on August 4, 2025, with total revenue of $2.96 billion, up 12% year over year. U.S. revenue rose 14% to $1.85 billion on strong demand and favorable gross-to-net, while ex-U.S. revenue grew 8% to $1.12 billion. GAAP net income was $1.03 billion ($3.99 diluted EPS) versus a $3.6 billion net loss a year earlier, which was driven by the non-cash $4.4 billion Alpine acquired IPR&D charge. Comparisons are therefore distorted, and the underlying trend is better judged on revenue growth and non-GAAP figures, with non-GAAP net income of $1.17 billion ($4.52 per diluted share). Cash and marketable securities reached $12.0 billion. Vertex reiterated full-year 2025 guidance, including revenue of $11.85 to $12.0 billion and non-GAAP effective tax rate of 20.5% to 21.5%. Growth is being driven by the cystic fibrosis franchise, where TRIKAFTA/KAFTRIO sales reached $2.55 billion, and by early contributions from three launches: ALYFTREK (CF, $157 million in the quarter), CASGEVY (sickle cell disease and beta thalassemia, $30 million), and JOURNAVX (non-opioid acute pain, $12 million). Management highlighted access gains for JOURNAVX, with coverage for nearly half of U.S. covered lives. The pipeline update included a discontinued monotherapy program (VX-993 in acute pain), a narrowed path in peripheral neuropathic pain, and reprioritized povetacicept indications, with a possible accelerated approval filing in IgAN in the first half of 2026. The filing also disclosed that Chief Scientific Officer David Altshuler will retire effective August 1, 2026, with Mark Bunnage, current SVP of Global Research, succeeding him effective February 1, 2026. This is a planned transition and not a disruption to guidance. Investors should watch launch uptake and reimbursement progress, the timing of pivotal readouts, and R&D spending levels in the second half of 2025.

Aug 4, 2025 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Corporate Update (May 19, 2025)

Vertex Pharmaceuticals Incorporated (VRTX) announced today a significant expansion of its capital return program with the authorization of a new $4.0 billion stock repurchase program, effective immediately. This new "2025 Repurchase Program" demonstrates management's confidence in the company's financial health and its commitment to enhancing shareholder value. The program has no expiration date and allows for flexibility in execution, including open market purchases and privately negotiated transactions, subject to market conditions and other strategic investment opportunities. This substantial new authorization complements the existing "2023 Repurchase Program," under which approximately $775 million remains available as of May 16, 2025. Combined, VRTX now has the authorization to repurchase up to $4.775 billion of its common stock. This aggressive buyback strategy signals a proactive approach to capital allocation, potentially reducing share count and increasing earnings per share over time, which should be viewed positively by investors.

May 19, 2025 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Shareholder Vote Results (May 14, 2025)

Vertex Pharmaceuticals Incorporated (VRTX) held its annual shareholder meeting on May 14, 2025, with the results of key votes detailed in this 8-K filing. The company's Board of Directors saw all eleven nominated members overwhelmingly re-elected, indicating strong shareholder confidence in the current leadership and governance. Furthermore, the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified by a significant majority of shareholders. Investors will also note the advisory approval of the 2024 executive compensation program. However, a shareholder proposal concerning 'excessive golden parachutes' was not approved, suggesting that current executive compensation structures, despite the advisory vote on the 2024 program, remain a point of contention or scrutiny for a portion of the shareholder base. Overall, the meeting reflects broad support for the company's direction and governance framework, with a minor exception regarding executive compensation policies.

May 14, 2025 10-Q

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q1 Ended Mar 31, 2025

Vertex Pharmaceuticals Inc. reported its first-quarter 2025 financial results, showing a slight increase in total revenues to $2.77 billion, up 3% year-over-year, primarily driven by the sustained performance of TRIKAFTA/KAFTRIO and the initial contributions from its new cystic fibrosis (CF) medicine, ALYFTREK. However, net income saw a significant decline of 41% to $646.3 million, compared to $1.1 billion in the prior year. This decrease was largely influenced by a substantial $379 million intangible asset impairment charge related to the discontinuation of the VX-264 clinical program for type 1 diabetes, and a decrease in acquired in-process research and development (AIPR&D) expenses. The company continues to invest heavily in research and development, with expenses rising 24% year-over-year, reflecting advancements across its diverse pipeline, including treatments for sickle cell disease (SCD), acute pain, and various rare diseases. The launch of JOURNAVX for acute pain has shown early traction with over 20,000 prescriptions written within its first two months. Despite the decrease in net income, Vertex maintains a strong liquidity position with over $11.3 billion in cash, cash equivalents, and marketable securities, supporting ongoing operations and strategic investments.

May 6, 2025 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (May 5, 2025)

Vertex Pharmaceuticals reported first-quarter 2025 results with total revenue of $2.77 billion, up 3% year over year, driven by TRIKAFTA/KAFTRIO (about $2.54 billion) and an early contribution from the U.S. launch of ALYFTREK. U.S. revenue rose 9% to $1.66 billion on strong demand and higher net realized pricing, while ex-U.S. revenue fell 5% to $1.11 billion, largely due to the expected revenue decline in Russia, where Vertex cites intellectual property violations. The company raised the low end of its full-year 2025 total revenue guidance by $100 million to $11.85–$12.0 billion, and reiterated its GAAP and non-GAAP expense and non-GAAP tax rate guidance. Profitability was mixed. GAAP net income fell to $646 million (diluted EPS $2.49) from $1.1 billion a year earlier, reflecting a $379.0 million intangible asset impairment tied to VX-264 (the cells-plus-device type 1 diabetes program, now discontinued) and higher operating spend. Non-GAAP net income was $1.1 billion (diluted EPS $4.06), down from $1.2 billion. Combined R&D, acquired IPR&D and SG&A expenses rose on pipeline investment and JOURNAVX commercial launch costs. Cash and marketable securities were $11.4 billion at quarter end, up from $11.2 billion, despite ongoing share repurchases. The quarter's pipeline and launch news was substantial. JOURNAVX (suzetrigine), the non-opioid acute pain drug, has broad early uptake with roughly 94 million lives with covered access and a formal agreement with a large PBM. Povetacicept has completed enrollment of its IgAN interim cohort, with a potential U.S. accelerated approval filing in the first half of 2026, and has moved into pivotal development in primary membranous nephropathy. Zimislecel's Phase 3 dosing is expected to complete in Q2 2025, with filings planned for 2026. Investors should note that the company's guidance is reaffirmed in its essentially unchanged expense outlook, and that the VX-522 MAD study was paused for a tolerability issue.

May 5, 2025 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Corporate Update (Mar 28, 2025)

Vertex Pharmaceuticals announced a significant update regarding its type 1 diabetes (T1D) program, specifically the VX-264 clinical trial. The company has decided not to advance VX-264 further in clinical development based on trial results. This decision necessitates an evaluation of intangible assets associated with the VX-264 program for impairment. Vertex currently anticipates a non-cash, intangible asset impairment charge of approximately $400 million. This charge will be recognized in GAAP operating expenses for the first quarter and the full year 2025. The company plans to provide detailed results of this impairment analysis in its upcoming Quarterly Report on Form 10-Q for the quarter ending March 31, 2025. Investors should note that this charge is non-cash and impacts operating expenses, not cash flow directly in the current period.

Mar 28, 2025 10-K

VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2024

Vertex Pharmaceuticals (VRTX) closed 2024 with net product revenues of $11.0 billion, up 12% from $9.9 billion in 2023, driven by TRIKAFTA/KAFTRIO demand, younger-age expansions, and higher U.S. net realized pricing. However, reported results swung to a net loss of $535.6 million (-$2.08 per diluted share), versus net income of $3.6 billion in 2023. The swing was driven by a $4.4 billion non-deductible acquired in-process R&D charge from the May 2024 acquisition of Alpine Immune Sciences (for approximately $5.0 billion in cash) and its lead asset povetacicept, which was expensed as an asset acquisition. Excluding this charge, the underlying business remained highly profitable, though operating expenses rose sharply with R&D up 15% to $3.6 billion and SG&A up 29% to $1.5 billion. Balance sheet liquidity fell as cash, equivalents and marketable securities declined to $11.2 billion from $13.7 billion, reflecting the Alpine purchase and $1.2 billion of share repurchases. Operating cash flow was negative $492.6 million for 2024 (versus $3.5 billion in 2023), largely due to the Alpine payment. Management expects product revenues to grow in 2025 from ALYFTREK (approved December 2024, once-daily triple combination), CASGEVY infusions, and the January 2025 launch of JOURNAVX, a non-opioid acute pain drug. The company has no debt drawn under its $500 million revolver and states cash flows should fund operations for at least twelve months. Key risks remain concentrated: substantially all product revenue comes from CF medicines, pricing pressure from the IRA and state PDABs, a December 2024 FDA boxed warning on liver injury for TRIKAFTA and ALYFTREK, and a pending patent trial against Lupin on KALYDECO granules scheduled for September 2025. The pipeline has several 2025 catalysts, including VX-522 mRNA data for CF, the AMPLITUDE and RAINIER interim analyses for potential accelerated approvals in AMKD and IgAN, and zimislecel Phase 3 enrollment in type 1 diabetes.

Feb 13, 2025 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Feb 10, 2025)

Vertex Pharmaceuticals (VRTX) reported fourth-quarter and full-year 2024 results on February 10, 2025. Full-year 2024 product revenue rose 12% to $11.02 billion, led by TRIKAFTA/KAFTRIO, with U.S. net product revenue up 11% to $6.68 billion and ex-U.S. revenue up 13% to $4.34 billion. However, GAAP results were sharply negative: a GAAP net loss of $(536) million (GAAP EPS of $(2.08)) reflected $4.6 billion of acquired IPR&D expense, mainly the roughly $4.4 billion associated with the Alpine Immune Sciences acquisition. Non-GAAP net income was $111 million ($0.42 per diluted share). Cash, cash equivalents and marketable securities fell to $11.2 billion from $13.7 billion, reflecting the Alpine cash consideration and share repurchases. management guided to FY2025 total revenue of $11.75 to $12.0 billion, with non-GAAP combined R&D, AIPR&D and SG&A expenses of $4.9 to $5.0 billion and a non-GAAP effective tax rate of 20.5% to 21.5%. Growth drivers include the U.S. launch of ALYFTREK (approved December 20, 2024, for ages 6+ with CF), the early launch of JOURNAVX (FDA-approved January 30, 2025, for moderate-to-severe acute pain), and continued CASGEVY uptake. The company also highlighted a broad late-stage pipeline, including pivotal programs in APOL1-mediated kidney disease, IgA nephropathy and type 1 diabetes. In a separate 8-K item, Vertex announced that Stuart Arbuckle, EVP and Chief Operating Officer, will retire effective July 1, 2025. CFO Charles (Charlie) Wagner, Jr. will add the COO role, and Duncan McKechnie, current SVP and head of North America Commercial, will become Chief Commercial Officer, both effective the same date. Wagner's new employment agreement sets a $1,000,000 base salary and a 100% target bonus, with defined severance and change-of-control protections.

Feb 10, 2025 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Regulation FD Disclosure (Dec 20, 2024)

Vertex Pharmaceuticals announced a significant milestone with the U.S. Food and Drug Administration's approval of ALYFTREK™ (vanzacaftor/tezacaftor/deutivacaftor) on December 19, 2024. This new therapy targets cystic fibrosis (CF) in patients aged 6 and older who possess at least one F508del mutation or another responsive mutation in the CFTR gene. The approval represents a key advancement in Vertex's CF franchise and offers a new treatment option for a broad segment of the CF patient population. The company has also set the wholesale acquisition cost (WAC) for ALYFTREK in the United States at $370,269 annually, or $28,404 per 28-day pack. This pricing, while substantial, is typical for advanced therapies in the rare disease space and will be a crucial factor for payers and patients to consider. Investors will be closely watching market uptake and reimbursement dynamics for ALYFTREK as it launches.

Dec 20, 2024 10-Q

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q3 Ended Sep 30, 2024

Vertex Pharmaceuticals Inc. reported solid third-quarter 2024 results, driven by strong performance in its cystic fibrosis (CF) franchise, particularly TRIKAFTA/KAFTRIO, which saw a 14% increase in revenue year-over-year. Overall product revenues grew 12% to $2.8 billion. Despite this revenue growth, the company reported a net loss of $1.45 billion for the first nine months of 2024, primarily due to a significant $4.4 billion acquired in-process research and development (AIPR&D) expense related to the acquisition of Alpine Immune Sciences, Inc. in May 2024. This acquisition, while substantial, brings a promising candidate, povetacicept, for IgA nephropathy. The company is also advancing its pipeline with key near-term launch opportunities including vanzacaftor/tezacaftor/deutivacaftor for CF (PDUFA date January 2, 2025) and suzetrigine for acute pain (PDUFA date January 30, 2025). Furthermore, Vertex continues to invest heavily in research and development, with expenses for the first nine months of 2024 totaling $2.6 billion, reflecting its commitment to its diverse pipeline across various therapeutic areas beyond CF.

Nov 5, 2024 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Nov 4, 2024)

Vertex Pharmaceuticals reported third quarter 2024 results on November 4, 2024, with product revenue of $2.77 billion, up 12% year over year, driven primarily by TRIKAFTA/KAFTRIO (up to $2.59 billion from $2.27 billion). U.S. product revenue grew 10% to $1.71 billion and ex-U.S. revenue grew 14% to $1.06 billion. The company raised its full-year 2024 product revenue guidance to $10.8–$10.9 billion from $10.65–$10.85 billion, while keeping its expense and acquired IPR&D guidance unchanged. GAAP net income was $1.0 billion ($4.01 diluted EPS) and non-GAAP net income was $1.1 billion ($4.38 diluted EPS), both roughly flat with Q3 2023 as higher R&D and SG&A spending offset revenue growth. Full-year 2024 results are heavily distorted by the $4.4 billion Alpine Immune Sciences acquisition-related IPR&D charge taken in Q2 2024, which drove nine-month GAAP net loss to $1.45 billion. Cash, cash equivalents and marketable securities fell to $11.2 billion from $13.7 billion at year-end 2023, reflecting the Alpine cash consideration and share repurchases. Investors should focus on the pipeline and launch catalysts: an FDA PDUFA date of January 2, 2025 for vanzacaftor triple in CF, and a PDUFA date of January 30, 2025 for suzetrigine in moderate-to-severe acute pain. Three programs (suzetrigine in DPN, povetacicept in IgAN, and VX-880 in T1D) advanced to Phase 3 during the quarter. The press release is furnished under Item 2.02 rather than filed, so its contents are not subject to Section 18 liability unless specifically incorporated by reference into another filing.

Nov 4, 2024 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Material Agreement (Aug 16, 2024)

Vertex Pharmaceuticals Incorporated (VRTX) has entered into material definitive agreements by amending its headquarters leases for approximately 1.1 million square feet of office and laboratory space in Boston, MA. The amendments extend the lease terms for the properties at 50 Northern Avenue and 11 Fan Pier Boulevard significantly, from the current expiration of December 2028 to June 30, 2044. This provides Vertex with long-term stability and a strategic operational base in a key biotech hub. This extension demonstrates a commitment to Vertex's current Boston headquarters and suggests confidence in its ongoing operations and future growth plans within this location. Investors can view this as a positive development, ensuring continuity and a stable environment for research, development, and administrative functions for at least the next two decades, with options for further extensions.

Aug 16, 2024 10-Q

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q2 Ended Jun 30, 2024

Vertex Pharmaceuticals Inc. reported its second-quarter and first-half 2024 financial results, highlighting continued revenue growth driven by its cystic fibrosis (CF) franchise, particularly TRIKAFTA/KAFTRIO. Despite a significant net loss for the period, largely due to a substantial acquired in-process research and development (AIPR&D) charge related to the acquisition of Alpine Immune Sciences, Inc., the company's core product revenue remains strong. Key developments include the acquisition of Alpine, which significantly impacted the quarter's financials but brought povetacicept into the pipeline for kidney diseases. Vertex is also progressing with its non-CF pipeline, with notable advancements in its sickle cell disease therapy, CASGEVY, and upcoming potential launches for vanzacaftor/tezacaftor/deutivacaftor in CF and suzetrigine for acute pain. The company's liquidity remains robust, although cash reserves have decreased due to the Alpine acquisition.

Aug 2, 2024 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Aug 1, 2024)

Vertex Pharmaceuticals reported Q2 2024 results that were dominated by a one-time charge tied to its acquisition of Alpine Immune Sciences. Product revenue rose 6% year over year to $2.65 billion, led by TRIKAFTA/KAFTRIO, with U.S. net product revenue up 7% to $1.61 billion and ex-U.S. up 5% to $1.03 billion. However, Acquired IPR&D expense jumped to $4.4 billion (versus $111 million a year earlier), producing a GAAP net loss of $3.6 billion, or $(13.92) per diluted share, compared with net income of $916 million in Q2 2023. Non-GAAP net loss was $3.3 billion, or $(12.83) per share. Management raised full-year 2024 product revenue guidance to $10.65-$10.85 billion from $10.55-$10.75 billion. The company now expects combined GAAP R&D and SG&A of $5.0-$5.2 billion, and AIPR&D expense of about $4.6 billion, with a non-GAAP effective tax rate near 100% because the Alpine charge is non-deductible. Cash, equivalents and marketable securities fell to $10.2 billion from $13.7 billion, reflecting roughly $5.0 billion of cash paid for Alpine. The filing also highlights regulatory momentum. The FDA accepted the vanzacaftor triple NDA (PDUFA January 2, 2025) and suzetrigine NDA (PDUFA January 30, 2025), both with Priority Review. Investors should weigh the strong revenue trajectory and pipeline catalysts against the sharp near-term earnings and tax-rate distortion, and the reduced cash cushion, while recognizing that the AIPR&D charge is a non-cash-like accounting event tied to the Alpine deal.

Aug 1, 2024 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Corporate Update (Jun 27, 2024)

Vertex Pharmaceuticals Inc. (VRTX) filed an 8-K on June 27, 2024, to provide an update on the accounting treatment and financial impact of its previously announced acquisition of Alpine Immune Sciences, Inc. The company expects to account for the acquisition as an asset acquisition, which will result in a significant one-time, non-deductible Acquired In-Process Research & Development (AIPR&D) expense of approximately $4.4 billion in the second quarter of 2024. This expense will impact both GAAP and non-GAAP reported operating expenses and net income, and will influence the company's financial guidance for the full year 2024. In addition to the AIPR&D charge, Vertex anticipates incurring approximately $200 million in transaction-related compensation expense due to the acceleration of unvested Alpine awards. This compensation expense will also affect reported GAAP operating expenses and net income for the current quarter and the full year. Despite these significant non-recurring charges, Vertex reaffirms its expectation to absorb Alpine's non-GAAP R&D and SG&A expenses within its previously provided operating expense guidance range for the remainder of 2024.

Jun 27, 2024 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Corporate Update (May 20, 2024)

On May 20, 2024, Vertex Pharmaceuticals (VRTX) completed its acquisition of Alpine Immune Sciences, Inc. (Alpine) for approximately $5.0 billion in equity value. The deal was executed under the Merger Agreement signed April 10, 2024, following a tender offer. Upon completion of the tender offer, Vertex's wholly owned subsidiary, Adams Merger Sub, Inc., merged with and into Alpine under Section 251(h) of the Delaware General Corporation Law. This allowed the merger to close without an Alpine stockholder meeting, with Alpine surviving as a wholly owned subsidiary of Vertex. The filing is largely a completion notice rather than a source of new financial results. Its main investor-relevant disclosure is that Vertex will finalize the accounting treatment for the acquisition during the second quarter of 2024, which means the purchase price allocation and related accounting conclusions remain pending in this filing. The filing also incorporates the full Merger Agreement by reference, with schedules omitted under Regulation S-K Item 601(b)(2). For investors, the key takeaways are the size of the transaction, the speed of execution from signing to closing (about six weeks), and the structure, which avoided a lengthy stockholder vote. The filing does not disclose the deal's strategic rationale, financing details, or the expected revenue or earnings impact, so those points would need to be sought in Vertex's earnings materials or other disclosures.

May 20, 2024 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Shareholder Vote Results (May 15, 2024)

Vertex Pharmaceuticals Incorporated (VRTX) filed an 8-K report on May 15, 2024, detailing the results of their Annual Meeting of Shareholders held on May 15, 2024. The key takeaway for investors is the overwhelming shareholder support for the company's current leadership and operational direction. All incumbent directors were re-elected with substantial 'For' votes, indicating strong confidence in their stewardship. Furthermore, shareholders ratified the appointment of Ernst & Young LLP as the independent auditor and approved, on an advisory basis, the executive compensation program. These results suggest alignment between management and shareholders on corporate governance and financial oversight. While the majority of proposals received significant shareholder approval, it is noteworthy that two shareholder proposals were put to a vote. One proposal regarding special shareholder meeting improvements was approved, while a proposal for a report on racial and gender pay gaps was not approved. These outcomes provide insight into shareholder priorities and areas where the company may need to address investor concerns moving forward.

May 15, 2024 10-Q

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q1 Ended Mar 31, 2024

Vertex Pharmaceuticals reported strong financial results for the first quarter of 2024, showcasing significant year-over-year growth in product revenues and a substantial increase in net income. Product revenues rose by 13% to $2.7 billion, driven primarily by the continued strong performance of TRIKAFTA/KAFTRIO in international markets and expanded use in younger age groups in the U.S. This revenue growth, coupled with a strategic decrease in acquired in-process R&D expenses, led to a 46% surge in income from operations and a 57% increase in net income to $1.1 billion. The company's expanding pipeline and recent regulatory approvals, such as CASGEVY for sickle cell disease, highlight its ongoing commitment to innovation and its potential for future growth across multiple therapeutic areas. Financially, Vertex maintains a robust liquidity position with $14.6 billion in cash, cash equivalents, and marketable securities. The company is actively managing its capital, including a substantial share repurchase program and significant investments in R&D. The upcoming acquisition of Alpine Immune Sciences for approximately $4.9 billion underscores Vertex's strategy to bolster its pipeline with promising external assets, particularly in kidney disease. Despite ongoing R&D investments and strategic capital deployment, the company's financial strength and diversified therapeutic focus position it well for continued development and commercial success.

May 7, 2024 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (May 6, 2024)

Vertex Pharmaceuticals reported first quarter 2024 results on May 6, 2024, with product revenue of $2.69 billion, up 13% year over year. U.S. net product revenue rose 8% to $1.52 billion and ex-U.S. revenue rose 21% to $1.17 billion, driven by TRIKAFTA/KAFTRIO uptake including younger patient label expansions. GAAP net income increased 57% to $1.10 billion ($4.21 diluted EPS) and non-GAAP net income rose 56% to $1.24 billion ($4.76 non-GAAP diluted EPS). Profit growth was supported by higher product revenue and lower acquired IPR&D expense, which fell from $347.1 million to $76.8 million. Cash, cash equivalents and marketable securities reached $14.6 billion, up from $13.7 billion at year-end 2023. Vertex reiterated full year 2024 guidance, including product revenue of $10.55 to $10.75 billion and combined non-GAAP R&D, acquired IPR&D and SG&A expenses of $4.3 to $4.4 billion. The company also highlighted regulatory progress: submissions for the vanzacaftor triple in cystic fibrosis to the FDA and EMA, a rolling NDA for suzetrigine in moderate-to-severe acute pain expected to complete in Q2 2024, and CASGEVY launches in several geographies. The announced acquisition of Alpine Immune Sciences for approximately $4.9 billion in cash, which adds povetacicept for IgA nephropathy, is expected to close in the second quarter of 2024. Investors should note that the press release's financial figures reflect a strong quarter, but the outlook depends on successful regulatory approvals, CASGEVY reimbursement and uptake, and the Alpine integration. The filing also notes that the Exhibit 99.1 press release is furnished rather than filed, so its content is not subject to Section 18 liability unless specifically incorporated into another filing.

May 6, 2024 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Material Agreement (Apr 11, 2024)

Vertex Pharmaceuticals Inc. (VRTX) has announced a significant development through an 8-K filing on April 11, 2024, detailing a definitive merger agreement to acquire Alpine Immune Sciences, Inc. The acquisition will be conducted via a cash tender offer at $65.00 per share, valuing the transaction at approximately $65.00 per share, net to the seller in cash. This strategic move aims to bolster Vertex's pipeline, particularly in the realm of autoimmune and kidney diseases, aligning with its focus on developing innovative therapies for serious diseases. The transaction is not subject to a financing condition, indicating Vertex has secured the necessary capital. The deal is expected to close within approximately one year, pending customary closing conditions, including regulatory approvals and the successful tender of a majority of Alpine's outstanding shares. Key Alpine shareholders, collectively holding about 25.5% of the outstanding shares, have entered into tender and support agreements, indicating strong backing for the transaction.

Apr 11, 2024 10-K

VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2023

Vertex Pharmaceuticals' FY2023 10-K shows a company whose financial profile is dominated by its cystic fibrosis franchise. Net product revenues rose 11% to $9.87 billion, driven by strong ex-U.S. uptake and label expansions of TRIKAFTA/KAFTRIO, with TRIKAFTA/KAFTRIO alone generating $8.94 billion (up 16%). Income from operations fell 11% to $3.83 billion because operating expenses rose 31% to $6.04 billion, reflecting higher R&D, $527 million of acquired in-process R&D, and pre-launch SG&A. Net income grew 9% to $3.62 billion, or $13.89 per diluted share, helped by a $548 million swing to other non-operating income driven mainly by interest income of $615 million. The effective tax rate fell to 17.4% from 21.5%, though cash taxes paid rose sharply to $1.68 billion. Operating cash flow declined to $3.54 billion from $4.13 billion, and total cash and marketable securities reached $13.7 billion. The filing's key forward-looking catalysts are the planned mid-2024 global filings for the once-daily triple combination vanzacaftor/tezacaftor/deutivacaftor and the planned mid-2024 NDA for the non-opioid pain candidate VX-548, plus the CASGEVY launch for sickle cell disease and beta thalassemia, which is expected to be a foundational but early-revenue year. Risks include heavy concentration in CF revenue, the Inflation Reduction Act and state drug-pricing pressure, the pause of the VX-880 type 1 diabetes trial after two patient deaths, and pending patent litigation over KALYDECO generics, with several settlements already reached. For investors, the central question is whether the CF franchise can keep compounding while the company funds a large, costly pipeline and multiple first-time launches. The company has ample liquidity to self-fund these efforts and continued share repurchases under a $3.0 billion program, with $2.6 billion remaining.

Feb 15, 2024 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Feb 5, 2024)

Vertex Pharmaceuticals (VRTX) reported fourth quarter and full-year 2023 results on February 5, 2024, filed under Item 2.02 with the press release attached as Exhibit 99.1. Full-year 2023 product revenue rose 11% to $9.87 billion, driven by TRIKAFTA/KAFTRIO in ex-U.S. markets and continued TRIKAFTA growth in the U.S., including the launch in children aged 2 to 5. U.S. product revenue grew 6% to $6.04 billion, while ex-U.S. revenue grew 18% to $3.83 billion. Full-year GAAP net income rose 9% to $3.62 billion, and non-GAAP net income rose 3% to $3.97 billion. Cash and marketable securities ended the year at $13.7 billion, up from $10.9 billion. Note that the balance sheet in the filing shows $11.2 billion of cash and marketable securities plus $2.5 billion of long-term marketable securities, which together account for the $13.7 billion figure. Management guided to 2024 product revenue of $10.55 to $10.75 billion, with non-GAAP R&D, acquired IPR&D and SG&A expenses of $4.3 to $4.4 billion and a non-GAAP effective tax rate of 20% to 21%. Combined GAAP expenses are guided to $4.9 to $5.1 billion, and the gap is mainly stock-based compensation. Combined expense growth in 2023 was elevated by acquired IPR&D, which rose to $527 million from $116 million. Fourth-quarter product revenue grew 9% to $2.52 billion, but GAAP operating income fell about 4% year over year to $988.5 million as R&D and SG&A costs rose. The main investor catalysts are regulatory and commercial. Vertex plans to file NDAs and related applications by mid-2024 for vanzacaftor/tezacaftor/deutivacaftor in CF and for VX-548 in acute pain. CASGEVY has been approved in the U.S., Great Britain, Bahrain and Saudi Arabia for sickle cell disease and transfusion-dependent beta thalassemia, and the company is working to secure reimbursement and expand treatment centers. Pipeline milestones include the inaxaplin Phase 3 start in APOL1-mediated kidney disease in Q1 2024, and VX-880 remains on a protocol-specified pause.

Feb 5, 2024 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Corporate Update (Dec 8, 2023)

Vertex Pharmaceuticals Inc. (VRTX) announced a significant development on December 8, 2023, with the U.S. Food and Drug Administration (FDA) approval of CASGEVY™ (exagamglogene autotemcel). This groundbreaking therapy is an autologous, genome-edited hematopoietic stem cell-based gene therapy designed for the treatment of sickle cell disease (SCD) in patients aged 12 and older who experience recurrent vaso-occlusive crises. This approval marks a major milestone for Vertex and offers a potentially transformative treatment option for a patient population with high unmet medical needs.

Dec 8, 2023 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Executive Changes (Dec 5, 2023)

Vertex Pharmaceuticals Incorporated announced a significant addition to its Board of Directors with the appointment of Nancy Thornberry, effective December 5, 2023. This appointment increases the size of the Board from ten to eleven members, indicating the company's strategic growth and the need for expanded oversight. Ms. Thornberry brings a wealth of experience from her extensive career in the biotechnology and pharmaceutical sectors, including her recent role as CEO of Kallyope, Inc., and significant leadership positions at Merck & Co., Inc. Her background in R&D and executive leadership is expected to provide valuable strategic guidance to Vertex. In addition to her operational expertise, Ms. Thornberry is an experienced board member, currently serving on the boards of Denali Therapeutics, Inc. and Schrödinger, Inc. Her compensation for joining the Vertex Board includes a substantial $400,000 restricted stock unit award, vesting in December 2024. This equity award aligns her interests with those of shareholders and underscores the company's commitment to attracting high-caliber talent to its leadership. Investors should view this as a positive development, signaling a strengthening of the company's governance and strategic capabilities.

Dec 5, 2023 10-Q

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q3 Ended Sep 30, 2023

Vertex Pharmaceuticals Inc. reported a solid third quarter and first nine months of 2023, demonstrating continued revenue growth driven by its cystic fibrosis (CF) franchise, particularly TRIKAFTA/KAFTRIO. Total product revenues reached $2.48 billion for the third quarter, an increase of 6% year-over-year, and $7.35 billion for the nine-month period, up 11%. Net income also saw a healthy increase, rising to $1.04 billion for the quarter and $2.65 billion for the nine months. The company is actively investing in its R&D pipeline, with significant increases in R&D and acquired in-process R&D expenses, reflecting progress in key therapeutic areas beyond CF, including sickle cell disease, beta-thalassemia, and various pain and kidney disease programs. Financially, Vertex maintains a strong liquidity position, with cash, cash equivalents, and marketable securities totaling $13.6 billion as of September 30, 2023. The company also continues to execute its capital allocation strategy, evidenced by the $2.7 billion remaining authorization for share repurchases. Upcoming catalysts include regulatory decisions for exa-cel in sickle cell disease and beta-thalassemia, as well as anticipated results from pivotal clinical trials for vanzacaftor/tezacaftor/deutivacaftor in CF and VX-548 in acute pain, positioning the company for potential future growth.

Nov 7, 2023 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Nov 6, 2023)

Vertex Pharmaceuticals reported third quarter 2023 results on November 6, 2023, showing product revenue of $2.48 billion, up 6% year over year, with U.S. net product revenue up 7% to $1.55 billion and ex-U.S. up 6% to $929 million. GAAP net income rose 11% to $1.04 billion ($3.97 diluted EPS), while non-GAAP net income rose 2% to $1.06 billion ($4.08 non-GAAP diluted EPS). Growth was driven by TRIKAFTA/KAFTRIO, including the launch in children aged 2 to 5 in the U.S. and reimbursement gains abroad, though TRIKAFTA/KAFTRIO growth was partly offset by a 56% decline in other CF products, which fell to $209 million. Management raised full-year 2023 CF product revenue guidance to approximately $9.85 billion from $9.7 to $9.8 billion, and reiterated combined non-GAAP R&D, acquired IPR&D and SG&A expense guidance at $4.1 to $4.2 billion. Operating expenses rose sharply, with combined non-GAAP R&D, acquired IPR&D and SG&A up about 31% year over year to $993 million in the quarter, reflecting late-stage pipeline investment and launch preparation. The GAAP effective tax rate fell to 12.2% due to R&D tax credits, which included a $74 million discrete benefit. Cash, cash equivalents and marketable securities were $13.6 billion at quarter end. The key near-term catalysts are the December 8, 2023 PDUFA date for exa-cel in sickle cell disease following an FDA advisory committee meeting, completion of pivotal Phase 3 studies for vanzacaftor triple combination in CF and VX-548 in acute pain by year-end 2023 with data expected in early 2024, and Phase 2 VX-548 data in diabetic peripheral neuropathy in late 2023. Investors should note that the guidance and pipeline timelines are forward-looking and subject to regulatory and clinical risk.

Nov 6, 2023 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Executive Changes (Oct 5, 2023)

Vertex Pharmaceuticals Inc. (VRTX) announced a significant change to its board of directors with the appointment of Michel Lagarde, effective October 5, 2023. Mr. Lagarde brings extensive experience from leadership roles at Thermo Fisher Scientific, including his current position as Executive Vice President and Chief Operating Officer. His background also includes experience in private equity within the healthcare sector, suggesting a valuable addition to Vertex's strategic oversight. This appointment increases the size of the Board from nine to ten members. Mr. Lagarde's compensation for joining the board includes a substantial $400,000 restricted stock unit award, which is scheduled to vest in October 2024. This signals a commitment to aligning director interests with shareholder value. The filing also confirms no related-party transactions or specific appointment understandings requiring further disclosure.

Oct 5, 2023 10-Q

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q2 Ended Jun 30, 2023

Vertex Pharmaceuticals reported strong financial results for the quarter ending June 30, 2023, with net product revenues increasing by 14% year-over-year to $2.5 billion. This growth was primarily driven by the continued strong performance and international uptake of TRIKAFTA/KAFTRIO, as well as its recent label expansion into younger age groups. Despite a significant increase in operating expenses, largely due to R&D investments in pipeline advancement and preparation for new product launches, net income rose by 13% to $915.7 million. The company is strategically investing in its diverse pipeline, with several key programs in late-stage development, including exa-cel for sickle cell disease and beta thalassemia, vanzacaftor/tezacaftor/deutivacaftor for cystic fibrosis, and VX-548 for acute pain. The positive momentum in the core CF business, coupled with promising developments across multiple therapeutic areas, positions Vertex for continued growth and potential market leadership beyond its established CF franchise. The company maintains a robust liquidity position with $12.6 billion in cash, cash equivalents, and marketable securities, providing ample resources to fund its ongoing operations and strategic initiatives.

Aug 2, 2023 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Aug 1, 2023)

Vertex Pharmaceuticals reported second quarter 2023 results on August 1, 2023, with product revenue of $2.49 billion, up 14% year over year, led by TRIKAFTA/KAFTRIO growth both in the U.S. (+7% to $1.51 billion) and internationally (+26% to $985 million). GAAP net income rose 13% to $915.7 million (diluted EPS $3.52), and non-GAAP net income rose 9% to $1.01 billion (non-GAAP diluted EPS $3.89). Cash, cash equivalents and marketable securities reached $12.6 billion at June 30, 2023, up from $10.9 billion at year-end 2022, supported by strong operating cash flow. Management raised full-year 2023 CF product revenue guidance to $9.7 to $9.8 billion from $9.55 to $9.7 billion, net of an approximately 150-basis-point foreign currency headwind. Combined non-GAAP R&D, acquired IPR&D and SG&A expense guidance was raised to $4.1 to $4.2 billion from $3.9 to $4.0 billion, driven partly by higher acquired IPR&D, including a $70 million milestone payment to CRISPR Therapeutics. The non-GAAP tax rate guidance was unchanged, and the company does not guide GAAP tax rate. The pipeline news was the main catalyst: FDA accepted the exa-cel BLAs for severe sickle cell disease (Priority Review, PDUFA date December 8, 2023) and transfusion-dependent beta thalassemia (PDUFA date March 30, 2024), with an FDA advisory committee planned. Vertex also expects completion of the SKYLINE and RIDGELINE vanzacaftor triple studies by year-end 2023 and VX-548 pivotal acute pain program results in late 2023 or early 2024. Investors should note that the advisory committee and the regulatory timelines are the key near-term risks to monitor.

Aug 1, 2023 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Shareholder Vote Results (May 18, 2023)

Vertex Pharmaceuticals Incorporated held its annual shareholder meeting on May 17, 2023, where key governance and executive matters were put to a vote. The meeting resulted in the overwhelming re-election of all nine nominated directors to the Board, with each director receiving substantial support. Shareholders also overwhelmingly ratified the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2023, indicating strong confidence in the company's audit oversight. Furthermore, the advisory vote on the 2022 executive compensation program showed significant shareholder approval, though with a notable percentage of opposition. In line with shareholder preference, the Board has determined that future advisory votes on executive compensation will be held annually. This consistency in director elections and auditor ratification, coupled with a clear direction on executive compensation voting frequency, reflects a stable corporate governance framework for Vertex Pharmaceuticals.

May 18, 2023 10-Q

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q1 Ended Mar 31, 2023

Vertex Pharmaceuticals Inc. reported strong financial performance for the first quarter of 2023, with net product revenues reaching $2.37 billion, a 13% increase year-over-year, driven primarily by the continued uptake of TRIKAFTA/KAFTRIO. While overall net income saw a slight decrease to $699.8 million from $762.1 million in the prior year, this was largely influenced by a significant increase in Acquired In-Process Research and Development (AIPR&D) expenses, totaling $347.1 million, up from $2.0 million in Q1 2022, reflecting substantial investments in strategic collaborations and licensing agreements. The company continues to invest heavily in its pipeline, with Research and Development expenses increasing by 24% to $742.6 million. This investment is supporting a broad range of programs targeting serious diseases beyond cystic fibrosis, including sickle cell disease, beta-thalassemia, neuropathic pain, and type 1 diabetes. Vertex also announced a new $3.0 billion share repurchase program, demonstrating a commitment to returning capital to shareholders while maintaining a robust cash position of $11.5 billion in cash, cash equivalents, and marketable securities.

May 2, 2023 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (May 1, 2023)

Vertex Pharmaceuticals reported first quarter 2023 results on May 1, 2023, with product revenue of $2.37 billion, up 13% year over year, driven mainly by strong international uptake of TRIKAFTA/KAFTRIO and continued U.S. performance of TRIKAFTA. U.S. product revenue rose 3% to $1.40 billion, while ex-U.S. revenue grew 33% to $971 million. Profitability declined: GAAP net income fell 8% to $699.8 million ($2.69 diluted EPS) and non-GAAP net income fell 12% to $794.0 million ($3.05 non-GAAP diluted EPS). The decline reflects a $347.1 million acquired IPR&D charge (versus $2.0 million a year earlier), higher clinical-stage R&D spending, and launch-related costs. Interest income rose sharply to $122.6 million from $1.6 million, partly offsetting these pressures. Management reiterated full-year 2023 guidance, including CF product revenue of $9.55 to $9.7 billion, combined non-GAAP R&D, acquired IPR&D and SG&A expenses of $3.9 to $4.0 billion, and a non-GAAP tax rate of 21% to 22%. The guidance includes an approximately 150-basis-point headwind from foreign currency. Cash, cash equivalents and marketable securities were $11.5 billion at quarter end, versus $10.9 billion at year end per the press release text, although the balance sheet in the exhibit shows $10.4 billion, a discrepancy investors should reconcile against the full filing. Operationally, the FDA approved TRIKAFTA for children aged 2 to 5, adding about 900 newly eligible patients, and Vertex completed the rolling U.S. BLA submissions for exa-cel in sickle cell disease and beta thalassemia, with Priority Review requested. Vertex also advanced its pipeline in type 1 diabetes, AAT deficiency and APOL1-mediated kidney disease, and made external investments including a $100 million upfront payment to CRISPR Therapeutics and roughly $225 million plus a $25 million equity investment in Entrada Therapeutics.

May 1, 2023 10-K

VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2022

Vertex Pharmaceuticals' FY2022 10-K shows a company whose growth is almost entirely driven by cystic fibrosis (CF). Net product revenues rose 18% to $8.93 billion, led by TRIKAFTA/KAFTRIO, which generated $7.69 billion (up 35%). Operating income more than doubled from a year earlier to $4.31 billion, though that comparison is flattered by the $900 million CRISPR upfront payment booked in 2021. Net income reached $3.32 billion, or $12.82 per diluted share, up from $9.01. Operating cash flow was $4.13 billion, and cash and marketable securities grew to $10.8 billion. Investors should note that the four CF medicines still account for virtually all product revenue, and that the older CF products (ORKAMBI, SYMDEKO/SYMKEVI, KALYDECO) are declining as patients switch to TRIKAFTA. The pipeline is the main source of optionality. Key programs include exa-cel (CRISPR-based gene editing for sickle cell disease and beta thalassemia, with a BLA in rolling submission), VX-548 (a non-opioid NaV1.8 pain candidate in Phase 3), inaxaplin (APOL1-mediated kidney disease, Phase 2/3), and VX-880 (stem-cell-derived islet cells for type 1 diabetes). The next-generation triple combination vanzacaftor/tezacaftor/deutivacaftor is in Phase 3, with data expected by the end of 2023. Management plans significant increases in R&D and SG&A spending in 2023 to prepare for these launches, which will pressure near-term margins. Balance-sheet strength supports this, and the board approved a new $3.0 billion share repurchase program in February 2023. The risk profile is concentrated. Substantially all revenue depends on CF, and a meaningful portion depends on the U.S. Inflation Reduction Act's Medicare drug price negotiation, along with ex-U.S. reimbursement timing. Customer concentration is high: McKesson accounted for 25% of gross product revenue. Patent litigation over KALYDECO generics is set for trial in 2024. A large uncertain tax liability rose sharply in 2022, and the effective tax rate increased to 21.5% from 14.2%. Pipeline setbacks, including the discontinuation of VX-814 in 2020 and the hold on the U.S. IND for VX-264, remain material execution risks.

Feb 10, 2023 8-K

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Feb 7, 2023)

Vertex Pharmaceuticals reported strong fourth-quarter and full-year 2022 results, with full-year product revenue of $8.93 billion, up 18% from 2021, driven mainly by rapid international uptake of TRIKAFTA/KAFTRIO and continued U.S. TRIKAFTA performance. GAAP net income rose 42% to $3.32 billion and non-GAAP net income rose 53% to $3.86 billion. The 2021 comparison was depressed by a one-time $900 million CRISPR payment, so much of the earnings improvement reflects lower acquired IPR&D rather than only operating growth. Fourth-quarter product revenue grew 11% to $2.30 billion, while fourth-quarter GAAP net income grew only 6%, reflecting higher R&D, launch costs and taxes. Management guided 2023 CF product revenue to $9.55–$9.7 billion and combined non-GAAP R&D, acquired IPR&D and SG&A expenses to $3.9–$4.0 billion, with a non-GAAP effective tax rate of 21–22%. The guidance includes an approximately 150-basis-point negative FX impact and roughly $300 million of upfront and milestone payments tied to existing collaborations and the anticipated Entrada Therapeutics deal. Cash and marketable securities reached $10.8 billion at year-end, and the board approved a new $3.0 billion share repurchase program with no expiration date. The company also outlined several potential near-term launches and regulatory milestones. These include exa-cel in sickle cell disease and beta thalassemia, where the EU and U.K. filings are validated and the U.S. rolling BLA is expected to be completed by end of Q1 2023. Pediatric TRIKAFTA/KAFTRIO (ages 2–5) has an FDA PDUFA date of April 28, 2023, and pediatric KALYDECO (infants from 1 month) has a PDUFA date of May 3, 2023. Pivotal Phase 3 work on VX-548 for acute pain continues, with completion expected in late 2023 or early 2024.

Feb 7, 2023 10-Q

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q3 Ended Sep 30, 2022

Vertex Pharmaceuticals reported strong financial performance for the nine months ended September 30, 2022, with total revenues reaching $6.63 billion, a 20% increase year-over-year, driven primarily by the continued success of TRIKAFTA/KAFTRIO. Net income for the period grew significantly to $2.50 billion, up 59% from the prior year, reflecting robust revenue growth and effective cost management, although the prior year's results were impacted by a large upfront payment for acquired in-process R&D. The company's balance sheet remains strong, with cash, cash equivalents, and marketable securities totaling $9.77 billion as of September 30, 2022. Vertex also made strategic advancements in its pipeline, notably the acquisition of ViaCyte, Inc., and continued progress in its gene-editing therapies for sickle cell disease and beta thalassemia.

Oct 28, 2022